Additional file 1: of Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Additional file 1: Table S1. of IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis

Susanna Lundström (4345954)
Aase Hensvold (3505412)
Dorothea Rutishauser (267236)
Lars Klareskog (4149)
A. Ytterberg (3417980)
Roman Zubarev (154182)
Anca Catrina (246690)

August 2017

Demographic characteristics of the nationwide EIRA cohort. Table S2. Characterized complement pathwa...

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

Seiji Nakamura (126240)
Katsuya Suzuki (1786093)
Hiroshi Iijima (3399872)
Yuko Hata (428188)
Chun Lim (3399875)
Yohei Ishizawa (3399869)
Hideto Kameda (3399878)
Koichi Amano (2543410)
Kenichi Matsubara (22850)
Ryo Matoba (1609)
Tsutomu Takeuchi (163145)

July 2016

Illustration of the distribution of patients in this observational study. (PDF 223 kb

Additional file 2: of Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Xavier Teitsma (3514304)
Wei Yang (109917)
Johannes Jacobs (3514301)
Attila Pethö-Schramm (4262878)
Michelle Borm (4262875)
Amy Harms (3007857)
Thomas Hankemeier (135670)
Jacob van Laar (213989)
Johannes Bijlsma (3424766)
Floris Lafeber (2301085)

October 2018

Overview of the pathway analysis in the (a) tocilizumab plus methotrexate, (b) tocilizumab, and (c) ...

Additional file 3: of Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy

Xavier Teitsma (3514304)
Johannes Jacobs (3514301)
Michal Mokry (236330)
Michelle Borm (4262875)
Attila PethĂś-Schramm (4262896)
Jacob van Laar (213989)
Johannes Bijlsma (3424766)
Floris Lafeber (2301085)

July 2017

Correlations and corresponding P values between the modules and achieving sustained drug-free remiss...

Additional file 2: of Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy

Xavier Teitsma (3514304)
Johannes Jacobs (3514301)
Michal Mokry (236330)
Michelle Borm (4262875)
Attila PethĂś-Schramm (4262896)
Jacob van Laar (213989)
Johannes Bijlsma (3424766)
Floris Lafeber (2301085)

July 2017

Description of the differentially co-expressed genes in the salmon module (tocilizumab plus methotre...

Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Xavier M Teitsma
Wei Yang
Johannes W G Jacobs
Attila Pethö-Schramm
Michelle E A Borm
Amy C Harms
Thomas Hankemeier
Jacob M van Laar
Johannes W J Bijlsma
Floris P J G Lafeber

October 2018

Abstract Background We previously identified, in newly diagnosed rheumatoid arthritis (RA) patients,...

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean DAS parameters and DAS responder rates over time in the total population. (PDF 111 kb

Additional file 1: of Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Josef Smolen (898)
Ronald van Vollenhoven (4148)
Arthur Kavanaugh (2683)
Vibeke Strand (410780)
Jiri Vencovsky (473759)
Michael Schiff (274089)
Robert LandewĂŠ (3445133)
Boulos Haraoui (63749)
Catherine Arendt (3584990)
Irina Mountian (3351668)
David Carter (117501)
DĂŠsirĂŠe van der Heijde (3445130)

September 2015

Supplementary material. Additional supplementary data tables and figures referred to in the manuscri...

Additional file 1: of Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Yoshiya Tanaka (186328)
Kazuteru Wada (6492581)
Yoshinori Takahashi (360065)
Owen Hagino (6492584)
Hubert Hoogstraten (6492587)
Neil Graham (181868)
Hideto Kameda (3399878)

March 2019

Table S1. Summary of clinical response after 4 and 12 weeks of treatment (mITT population plus first...

Additional file 2: of Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts

Kohjin Suzuki (4996409)
Kohsuke Yoshida (4996400)
Takeshi Ueha (119906)
Kenta Kaneshiro (4996394)
Ayako Nakai (4996385)
Naonori Hashimoto (4996415)
Koto Uchida (4996403)
Teppei Hashimoto (4996412)
Yoshiko Kawasaki (4996406)
Nao Shibanuma (4996388)
Natsuko Nakagawa (4996391)
Yoshitada Sakai (119945)
Akira Hashiramoto (4996397)

March 2018

Detailed information of patients with RA enrolled in this study. Joint samples obtained from 10 diff...

Additional file 1: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Proportion and adjusted risk ratio of patients who achieved therapy effectiveness based on the modif...

Additional file 2: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Rekha Narasimhan (5594711)
Roxana Coras (5594714)
Sara Rosenthal (5594717)
Shannon Sweeney (5594720)
Alessia Lodi (256296)
Stefano Tiziani (256302)
David Boyle (221745)
Arthur Kavanaugh (2683)
Monica Guma (814502)

August 2018

Figure S1. Correlation between synovial markers and serum metabolites. (TIFF 14826 kb

Additional file 4: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Rekha Narasimhan (5594711)
Roxana Coras (5594714)
Sara Rosenthal (5594717)
Shannon Sweeney (5594720)
Alessia Lodi (256296)
Stefano Tiziani (256302)
David Boyle (221745)
Arthur Kavanaugh (2683)
Monica Guma (814502)

August 2018

Figure S3. Correlation between serum metabolites and synovial CD19, CD79A, and IgGHC. (TIFF 14826 kb

Additional file 1: of The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study

Anna O’Connor (3117774)
Carter Thorne (3508292)
Hyeon Kang (3508295)
Diane Tin (786343)
Janet Pope (3464090)

August 2016

Comparison of mean change in outcome measurement scores between early period (0–6 weeks) and late pe...

Additional file 1: Table S1. of IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis

Susanna Lundström (4345954)
Aase Hensvold (3505412)
Dorothea Rutishauser (267236)
Lars Klareskog (4149)
A. Ytterberg (3417980)
Roman Zubarev (154182)
Anca Catrina (246690)

August 2017

Demographic characteristics of the nationwide EIRA cohort. Table S2. Characterized complement pathwa...

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

Seiji Nakamura (126240)
Katsuya Suzuki (1786093)
Hiroshi Iijima (3399872)
Yuko Hata (428188)
Chun Lim (3399875)
Yohei Ishizawa (3399869)
Hideto Kameda (3399878)
Koichi Amano (2543410)
Kenichi Matsubara (22850)
Ryo Matoba (1609)
Tsutomu Takeuchi (163145)

July 2016

Illustration of the distribution of patients in this observational study. (PDF 223 kb

Additional file 2: of Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Xavier Teitsma (3514304)
Wei Yang (109917)
Johannes Jacobs (3514301)
Attila Pethö-Schramm (4262878)
Michelle Borm (4262875)
Amy Harms (3007857)
Thomas Hankemeier (135670)
Jacob van Laar (213989)
Johannes Bijlsma (3424766)
Floris Lafeber (2301085)

October 2018

Overview of the pathway analysis in the (a) tocilizumab plus methotrexate, (b) tocilizumab, and (c) ...

Additional file 3: of Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy

Xavier Teitsma (3514304)
Johannes Jacobs (3514301)
Michal Mokry (236330)
Michelle Borm (4262875)
Attila PethĂś-Schramm (4262896)
Jacob van Laar (213989)
Johannes Bijlsma (3424766)
Floris Lafeber (2301085)

July 2017

Correlations and corresponding P values between the modules and achieving sustained drug-free remiss...

Additional file 2: of Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy

Xavier Teitsma (3514304)
Johannes Jacobs (3514301)
Michal Mokry (236330)
Michelle Borm (4262875)
Attila PethĂś-Schramm (4262896)
Jacob van Laar (213989)
Johannes Bijlsma (3424766)
Floris Lafeber (2301085)

July 2017

Description of the differentially co-expressed genes in the salmon module (tocilizumab plus methotre...

Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Xavier M Teitsma
Wei Yang
Johannes W G Jacobs
Attila Pethö-Schramm
Michelle E A Borm
Amy C Harms
Thomas Hankemeier
Jacob M van Laar
Johannes W J Bijlsma
Floris P J G Lafeber

October 2018

Abstract Background We previously identified, in newly diagnosed rheumatoid arthritis (RA) patients,...

Additional file 5: Figure S4. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

Mean DAS parameters and DAS responder rates over time in the total population. (PDF 111 kb

Additional file 1: of Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Josef Smolen (898)
Ronald van Vollenhoven (4148)
Arthur Kavanaugh (2683)
Vibeke Strand (410780)
Jiri Vencovsky (473759)
Michael Schiff (274089)
Robert LandewĂŠ (3445133)
Boulos Haraoui (63749)
Catherine Arendt (3584990)
Irina Mountian (3351668)
David Carter (117501)
DĂŠsirĂŠe van der Heijde (3445130)

September 2015

Supplementary material. Additional supplementary data tables and figures referred to in the manuscri...

Additional file 1: of Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Yoshiya Tanaka (186328)
Kazuteru Wada (6492581)
Yoshinori Takahashi (360065)
Owen Hagino (6492584)
Hubert Hoogstraten (6492587)
Neil Graham (181868)
Hideto Kameda (3399878)

March 2019

Table S1. Summary of clinical response after 4 and 12 weeks of treatment (mITT population plus first...

Additional file 2: of Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts

Kohjin Suzuki (4996409)
Kohsuke Yoshida (4996400)
Takeshi Ueha (119906)
Kenta Kaneshiro (4996394)
Ayako Nakai (4996385)
Naonori Hashimoto (4996415)
Koto Uchida (4996403)
Teppei Hashimoto (4996412)
Yoshiko Kawasaki (4996406)
Nao Shibanuma (4996388)
Natsuko Nakagawa (4996391)
Yoshitada Sakai (119945)
Akira Hashiramoto (4996397)

March 2018

Detailed information of patients with RA enrolled in this study. Joint samples obtained from 10 diff...

Additional file 1: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Marina Machado (4996619)
Cristiano Moura (4996613)
Steve Guerra (4996616)
Jeffrey Curtis (3442916)
Michal Abrahamowicz (129219)
Sasha Bernatsky (468773)

March 2018

Proportion and adjusted risk ratio of patients who achieved therapy effectiveness based on the modif...

Additional file 2: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Rekha Narasimhan (5594711)
Roxana Coras (5594714)
Sara Rosenthal (5594717)
Shannon Sweeney (5594720)
Alessia Lodi (256296)
Stefano Tiziani (256302)
David Boyle (221745)
Arthur Kavanaugh (2683)
Monica Guma (814502)

August 2018

Figure S1. Correlation between synovial markers and serum metabolites. (TIFF 14826 kb

Additional file 4: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Rekha Narasimhan (5594711)
Roxana Coras (5594714)
Sara Rosenthal (5594717)
Shannon Sweeney (5594720)
Alessia Lodi (256296)
Stefano Tiziani (256302)
David Boyle (221745)
Arthur Kavanaugh (2683)
Monica Guma (814502)

August 2018

Figure S3. Correlation between serum metabolites and synovial CD19, CD79A, and IgGHC. (TIFF 14826 kb

Additional file 1: of The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study

Anna O’Connor (3117774)
Carter Thorne (3508292)
Hyeon Kang (3508295)
Diane Tin (786343)
Janet Pope (3464090)

August 2016

Comparison of mean change in outcome measurement scores between early period (0–6 weeks) and late pe...

Additional file 1: Table S1. of IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis

Susanna Lundström (4345954)
Aase Hensvold (3505412)
Dorothea Rutishauser (267236)
Lars Klareskog (4149)
A. Ytterberg (3417980)
Roman Zubarev (154182)
Anca Catrina (246690)

August 2017

Demographic characteristics of the nationwide EIRA cohort. Table S2. Characterized complement pathwa...

Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Hisashi Yamanaka (137140)
Yoshiya Tanaka (186328)
Tsutomu Takeuchi (163145)
Naonobu Sugiyama (3476618)
Hirotoshi Yuasa (3476615)
Shigeyuki Toyoizumi (3476621)
Yosuke Morishima (812532)
Tomohiro Hirose (3077856)
Samuel Zwillich (3475445)

January 2016

ACR20 response rate and mean DAS28â4(ESR) and HAQ-DI over time for patients treated with tofacitin...

Additional file 1: of Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

Seiji Nakamura (126240)
Katsuya Suzuki (1786093)
Hiroshi Iijima (3399872)
Yuko Hata (428188)
Chun Lim (3399875)
Yohei Ishizawa (3399869)
Hideto Kameda (3399878)
Koichi Amano (2543410)
Kenichi Matsubara (22850)
Ryo Matoba (1609)
Tsutomu Takeuchi (163145)

July 2016

Illustration of the distribution of patients in this observational study. (PDF 223 kb

Additional file 1: of Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Abstract

Extracted data

Additional file 1: of Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Abstract

Extracted data

Related items

Related items